These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16136469)

  • 1. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects.
    Goepfert PA; Horton H; McElrath MJ; Gurunathan S; Ferrari G; Tomaras GD; Montefiori DC; Allen M; Chiu YL; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Keefer MC; Baden LR; Corey L;
    J Infect Dis; 2005 Oct; 192(7):1249-59. PubMed ID: 16136469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.
    Cao H; Kaleebu P; Hom D; Flores J; Agrawal D; Jones N; Serwanga J; Okello M; Walker C; Sheppard H; El-Habib R; Klein M; Mbidde E; Mugyenyi P; Walker B; Ellner J; Mugerwa R;
    J Infect Dis; 2003 Mar; 187(6):887-95. PubMed ID: 12660934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
    Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
    J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers.
    McFarland EJ; Johnson DC; Muresan P; Fenton T; Tomaras GD; McNamara J; Read JS; Douglas SD; Deville J; Gurwith M; Gurunathan S; Lambert JS
    AIDS; 2006 Jul; 20(11):1481-9. PubMed ID: 16847402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
    McElrath MJ; Corey L; Greenberg PD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults.
    Gorse GJ; Baden LR; Wecker M; Newman MJ; Ferrari G; Weinhold KJ; Livingston BD; Villafana TL; Li H; Noonan E; Russell ND;
    Vaccine; 2008 Jan; 26(2):215-23. PubMed ID: 18055072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
    Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
    J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.
    Cleghorn F; Pape JW; Schechter M; Bartholomew C; Sanchez J; Jack N; Metch BJ; Hansen M; Allen M; Cao H; Montefiori DC; Tomaras GD; Gurunathan S; Eastman DJ; do Lago RF; Jean S; Lama JR; Lawrence DN; Wright PF;
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):222-30. PubMed ID: 17693888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
    Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
    J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.
    Boyer JD; Cohen AD; Vogt S; Schumann K; Nath B; Ahn L; Lacy K; Bagarazzi ML; Higgins TJ; Baine Y; Ciccarelli RB; Ginsberg RS; MacGregor RR; Weiner DB
    J Infect Dis; 2000 Feb; 181(2):476-83. PubMed ID: 10669329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
    Gupta K; Hudgens M; Corey L; McElrath MJ; Weinhold K; Montefiori DC; Gorse GJ; Frey SE; Keefer MC; Evans TG; Dolin R; Schwartz DH; Harro C; Graham B; Spearman PW; Mulligan M; Goepfert P;
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):254-61. PubMed ID: 11873074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients.
    Ackers ML; Parekh B; Evans TG; Berman P; Phillips S; Allen M; McDougal JS
    J Infect Dis; 2003 Mar; 187(6):879-86. PubMed ID: 12660933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response".
    Jamieson BD; Ibarrondo FJ; Wong JT; Hausner MA; Ng HL; Fuerst M; Price C; Shih R; Elliott J; Hultin PM; Hultin LE; Anton PA; Yang OO
    Vaccine; 2006 Apr; 24(17):3426-31. PubMed ID: 16545508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.
    Russell ND; Graham BS; Keefer MC; McElrath MJ; Self SG; Weinhold KJ; Montefiori DC; Ferrari G; Horton H; Tomaras GD; Gurunathan S; Baglyos L; Frey SE; Mulligan MJ; Harro CD; Buchbinder SP; Baden LR; Blattner WA; Koblin BA; Corey L;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):203-12. PubMed ID: 17106277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
    Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
    Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.